Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Hahnel, Antje ^a   Wichmann, Henri ^a   Greither, Thomas ^a   Kappler, Matthias ^a   Würl, Peter ^b   Kotzsch, Matthias ^c   Taubert, Helge ^a,d,e   Vordermark, Dirk ^a   Bache, Matthias ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Diakoniekrankenhaus ^*  (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; OSTEOPONTIN; OSTEOPONTIN A; OSTEOPONTIN B; OSTEOPONTIN C; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; SOFT TISSUE SARCOMA; TUMOR LOCALIZATION; BLOOD; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; SARCOMA; SOFT TISSUE TUMOR;

FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859133038     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-131     Document Type: Article

References (27)

1. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87. 10.1016/j.tcb.2005.12.005, 16406521.
2. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27:103-118. 10.1007/s10555-007-9104-9, 18049863.
3. Vordermark D, Said HM, Katzer A, Kuhnt T, Hansgen G, Dunst J, Flentje M, Bache M. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006, 6:207. 10.1186/1471-2407-6-207, 1564036, 16911785.
4. Bache M, Kappler M, Said HM, Staab A, Vordermark D. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 2008, 15:322-338. 10.2174/092986708783497391, 18288988.
5. Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al Katib W, Postenka CO, Chambers AF. Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther 2005, 4:1336-1341. 10.4161/cbt.4.12.2166, 16258259.
6. Gaumann A, Petrow P, Mentzel T, Mayer E, Dahm M, Otto M, Kirkpatrick CJ, Kriegsmann J. Osteopontin expression in primary sarcomas of the pulmonary artery. Virchows Arch 2001, 439:668-674.
7. Sulzbacher I, Birner P, Trieb K, Lang S, Chott A. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 2002, 441:345-349. 10.1007/s00428-002-0671-4, 12404059.
8. Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Wurl P, Taubert H, Vordermark D. Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 2010, 10:132. 10.1186/1471-2407-10-132, 2856551, 20377868.
9. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995, 72:55-63.
10. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006, 25:2192-2202. 10.1038/sj.onc.1209248, 16288209.
11. Blasberg JD, Goparaju CM, Pass HI, Donington JS. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 2010, 139:1587-1593. 10.1016/j.jtcvs.2009.08.016, 2875279, 19818970.
12. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 2009, 35:1409-1416.
13. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ, Arafat HA. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 2009, 146:232-240. 10.1016/j.surg.2009.03.036, 2777713, 19628079.
14. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008, 122:889-897. 10.1002/ijc.23204, 17960616.
15. Patani N, Jouhra F, Jiang W, Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008, 28:4105-4110.
16. Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A, Pass HI. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun 2009, 382:514-518. 10.1016/j.bbrc.2009.03.042, 19285954.
17. Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P, You Y. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 2010, 12:765-775. 10.1093/neuonc/noq006, 2940675, 20511184.
18. Tilli TM, Franco V, Robbs B, Wanderley J, Silva F, Mello KD, Viola JP, Weber GF, Gimba ER. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 2011, 9:280-293. 10.1158/1541-7786.MCR-10-0463, 21263033.
19. Jahns F, Wilhelm A, Jablonowski N, Mothes H, Radeva M, Wolfert A, Greulich KO, Glei M. Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue. Carcinogenesis 2011, 32:913-920. 10.1093/carcin/bgr061, 21459756.
20. Wang HH, Wang XW, Tang CE. Osteopontin expression in nasopharyngeal carcinoma: its relevance to the clinical stage of the disease. J Cancer Res Ther 2011, 7:138-142. 10.4103/0973-1482.82926, 21768699.
21. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007, 26:6361-6371. 10.1038/sj.onc.1210463, 17452979.
22. Taubert H, Wurl P, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer 2010, 102:731-737. 10.1038/sj.bjc.6605520, 2837565, 20051950.
23. Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, Squire JA. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 2006, 6:237. 10.1186/1471-2407-6-237, 1609181, 17022822.
24. Miyajima J, Hayashi T, Saito K, Iida S, Matsuoka K. The Interaction between female sex hormone receptors and osteopontin in a rat hyperoxaluric model. Kurume Med J 2010, 57:73-80. 10.2739/kurumemedj.57.73, 21186342.
25. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6:757-764. 10.1016/S1470-2045(05)70292-8, 16198981.
26. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 2010, 5:82. 10.1186/1748-717X-5-82, 2949679, 20849637.
27. Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 2010, 5:e9633. 10.1371/journal.pone.0009633, 2835762, 20224789.